CORE F: SERUM ANALYTE AND BIOMARKER CORE

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 拟议的血清分析物和生物标志物核心旨在满足COBRE研究人员的需求，利用高通量蛋白质组学方法来测定人体血清或其他生物液体中的自身抗体，血清细胞因子，特异性抗体反应，血清激素水平和其他活动或生化代谢产物。通过COBRE临床核心和其他当地生物储存库中现有的生物储存库资源，COBRE研究人员可以获得数千份来自狼疮、类风湿性关节炎、干燥综合征和多发性硬化症患者的血清样本。研究者可以使用这些样本，或者专门为他们的项目获得的其他样本，可以使用本核心资源进行基于血清的生物标志物评价。 COBRE研究者将获得用于自身抗体高通量人类临床样本分析的多重微珠检测试剂盒和使用BioRad BioPlex 2200系统的其他检测试剂盒，以及基于Luminex的多重细胞因子检测试剂盒。为了评估抗体表位特异性和T细胞特异性，将继续之前肽核心的肽合成服务。最后，将评估和实施新的技术和方案，以利用进行额外的蛋白质组学，生物活性和生化测定的能力。 为实现这些目标，提出了以下四个目标： 目的/目标1：为人类和动物血清自身抗体检测提供具有成本效益的最新技术和方法。 目的/目标2：为COBRE研究人员提供高级建议和输入，以检测人类和动物样本中的细胞因子和趋化因子。 目的/目标3：提供固相肽合成和抗体检测的技术专长和性能。 宗旨/目标4：评估和获取新技术，开发血清蛋白质组学，生物活性或生化分析的新方法，可以进一步提高COBRE研究人员在临床转化界面进行尖端研究的能力。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The proposed Serum Analyte & Biomarker Core is designed to meet the needs of the COBRE investigators to utilize high-throughput proteomic methods to assay autoantibodies, serum cytokines, specific antibody responses, serum hormone levels and other activities or biochemical metabolites in human serum or other biofluids. Through the existing biorepository resources in the COBRE Clinical Core and other local biorespositories COBRE investigators have access to thousands of individual's serum samples from individuals with lupus, rheumatoid arthritis, Sj¿gren's syndrome and multiple sclerosis. Investigators can use these samples or others obtained specifically for their projects can be used in serum-based evaluation of biomarkers using the resources within this Core. COBRE investigators will be provided access to the multiplex bead-based assays for high-throughput human clinical sample analysis of autoantibody and other assays using the BioRad BioPlex2200 system, as well as Luminex based multiplex cytokine assays. To assess antibody epitope specificities and T cell specificities, the peptide synthesis services of the previous Peptide Core will be continued. Finally, new technologies and protocols will be assessed and implemented to take advantage of the ability toperform additional proteomic, bioactivity and biochemical assays. To accomplish these goals, the following four aims are proposed: Aim/Goal 1: Provide cost-effective access to current state-of-the-art technologies and methods for human and animal serum autoantibody testing. Aim/Goal 2: Provide COBRE investigators with senior level advice and input to cytokine and chemokine detection in human and animal samples. Aim/Goal 3: Offer access to technical expertise and performance of solid-phase peptide syntheses and antibody testing. Aim/Goal 4: Assess and acquire new technologies and develop new methods for the analysis of serum proteomic, bioactivity or biochemical assays that can further enhance the capabilities of the COBRE researchers to do cutting-edge research at the clinical-translational interface.